An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
July 24, 2018
End Date
June 28, 2022
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
July 24, 2018
End Date
June 28, 2022